US/UK/Canada

Share

Contacts

  • Cyxone AB
    Hyllie Boulevard 34, 215 32 Malmö, Sweden
    +46 708882172
    +46 708882172
    https://cyxone.com/en/

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -
    Tags ( Active)

    Cyxone receives patent approval from the US for the salt forms of the compound rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the company has obtained granted status for the US patent application 17/891,462 entitled Rabeximod Compounds from the United States Patent and Trademark Office (USPTO).The application covers the protection of salt forms of the compound rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The patent will be valid until 2042. ”We are delighted to receive the final approval for this important patent. It is an essential fundament for the future development and

    Cyxone receives Notice of Allowance from the US Patent Office for the protection of Rabeximod compound

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the US patent application 17/891,462 entitled Rabeximod Compounds. The application covers the protection of salt forms of the compound Rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent.

    Cyxone advances the patent portfolio for Rabeximod

    Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that national phase filings have been completed in a large number of relevant markets for four of its pending PCT applications directed to clinically applicable forms and formulations of Rabeximod, as well as their medical use, potentially conferring patent protection until 2041.In November 2020 Cyxone reported the filing of five new patent applications though the international patent cooperation treaty (PCT) in order to strengthen the intellectual property protection for Rabeximod. Cyxone today reports the

    Cyxone reports publication of four patent applications pertaining to its drug candidate Rabeximod

    Cyxone (publ) today announces that four patent applications pertaining to its drug candidate Rabeximod have been published by the PCT authority (WIPO). If approved, these patents have potential to prolong the market exclusivity of Rabeximod until 2041.The four patent applications published by the PCT authority (WIPO) are: [A] PCT/EP2021/065705 New Oral Formulation (this patent if granted is expected to give good protection for oral formulation of Rabeximod in crystalline form) [B] PCT/EP2021/065693 New Use of Rabeximod (this patent if granted is expected to give good protection for

    Cyxone files patent application with potential to extend market exclusivity of the drug candidate Rabeximod

    Cyxone (publ) today announces that the company has filed a new patent application for Rabeximod with patent authorities in key strategic territories. Approval of this new patent application on these markets, in conjunction with four additional patents filed during the period 2020–2021, will strengthen the intellectual property portfolio for Rabeximod and elongate the market exclusivity period until at least 2043.Rabeximod is a well-tolerated, orally available Phase 2 drug candidate that selectively targets the inflammatory macrophage – the central orchestrator of the inflammatory process.

    Cyxone files patent application to extend exclusivity of Rabeximod

    Cyxone (publ.) announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course. An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.Cyxone develops Rabeximod, a potentially disease modifying drug candidate for chronic diseases of the immune system as well as for critical conditions such as virally induced acute respiratory disorders. The candidate drug is subject to two

    Cyxone files new patent applications following additional innovation achievements

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the company has filed four patent applications for protection of new innovation achievements. The applications have been filed to relevant patent authorities.With these new patents, Cyxone will have wider protection for the company’s therapeutic scope as well as for the manufacturing and formulation processes. Cyxone is looking into opportunities to file more patent applications in the near future. Cyxone is unable to disclose more information regarding the filed patents at this point. The patents filed

    The Medical University of Vienna has filed a new patent application for extended protection of T20K, included in Cyxone’s license agreement

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the Medical University of Vienna has filed a new patent application for extended protection of T20K in multiple sclerosis (MS). The patent is included in Cyxone’s license agreement with the Medical University and is entitled “Cyclotides in combination with kappa opioid receptor ligands for multiple sclerosis therapy”.With this extended patent, Cyxone will have more therapeutic options for their cyclotides, a wider patent protection and a new priority date.   Contact Ola Skanung, interim CEO & CFO Tel:

    Cyxone announces issuance of U.S. divisional patent for drug candidate T20K in MS

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,159,710 B2 – a divisional patent related to the already approved ‘parent patent’ for drug candidate T20K in development for the treatment of multiple sclerosis (MS).The newly issued U.S. divisional patent is a sub-patent to the granted patent titled Cyclotides as immunosuppressive agents (US 9,453,052 B2). As stated in the application, this divisional patent relates to using the cyclotide-based drug candidate T20K in a pharmaceutical

    Cyxone receives notice of patent approval for immunosuppressant treatment with cyclotide T20K

    Cyxone announced today that the European Patent Office (EPO), has issued its formal intention to approve the company’s patent application regarding the company’s use of cyclotides as immunosuppressive drugs. The approval will strengthen the company’s patent portfolio and ensures the protection of the candidate T20K, which demonstrates beneficial pharmacological effect in preclinical studies against autoimmune diseases, such as multiple sclerosis (MS).Cyxone focuses on developing drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media